Short answer
Xeris Biopharma Holdings, Inc. (XERS) filed an 8-K current report with the SEC on June 5, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). 2026 annual meeting achieved quorum with 128,268,073 shares represented, or approximately 74% of outstanding shares.
Xeris Biopharma Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 2026 annual meeting achieved quorum with 128,268,073 shares represented, or approximately 74% of outstanding shares
- Dawn Halkuff and John Johnson elected as Class II directors through 2029, despite 40,780,330 broker non-votes
- Ernst & Young LLP appointment ratified for fiscal 2026 with 125,789,818 votes for
- Named executive compensation approved on an advisory basis with 82,230,204 votes for
- Director elections and say-on-pay results provide governance continuity, while broker non-votes materially influenced voting totals
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xeris Biopharma Holdings, Inc. 8-K filings
Get the next XERS 8-K as it lands
Follow XERS for push alerts, or ask the research agent what this filing means.